Poststroke spasticity management

Stroke

Volumn 43, Issue 11, 2012, Pages 3132-3136

  Francisco, Gerard E ^a,b   McGuire, John R ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UTHealth Motor Recovery Laboratory   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

muscle hypertonia; muscle spasticity; rehabilitation; stroke care; upper motor neuron disease

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; DANTROLENE; TIZANIDINE;

CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL RESEARCH; NEUROLYSIS; PHYSICAL MOBILITY; POSTSTROKE SPASTICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SPASTICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; MUSCLE SPASTICITY; STROKE;

EID: 84868193042     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.639831     Document Type: Review

References (55)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young R, Koella WP, eds. Spasticity: disordered Motor Control. Chicago, IL: Year Book Medical Publishers; 1980:485-494.
2. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: Its occurrence and association with motor impair-ments and activity limitations. Stroke. 2004;35:134-139.
3. Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010;41:2016-2020.
4. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515-522.
5. Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 2008;15:533-539.
6. Gomez-Medina O, Elovic E. Measurement tools and treatment out-comes in patients with spasticity. Spasticity Diagnosis and Management. New York, NY: Demos Medical; 2011:51-70.
7. Yelnik AP, Simon O, Parratte B, Gracies JM. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42:801-807.
8. Alibiglou L, Rymer WZ, Harvey RL, Mirbagheri MM. The relation between Ashworth scores and neuromechanical measurements of spas-ticity following stroke. J Neuroengineer Rehabil. 2008;5:18.
9. Blackburn M, van Vliet P, Mockett SP. Reliability of measurements obtained with the modified Ashworth scale in the lower extremities of people with stroke. Phys Ther. 2002;82:25-34.
10. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil. 1999;13:373-383.
11. Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia SC, Burke D. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil. 2000;81:1547-1555.
12. Stokic DS, Yablon SA, Hayes A. Comparison of clinical and neuro-physiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury. Arch Phys Med Rehabil. 2005;86:1801-1806.
13. Starsky AJ, Sangani SG, McGuire JR, Logan B, Schmit BD. Reliability of biomechanical spasticity measurements at the elbow of people poststroke. Arch Phys Med Rehabil. 2005;86:1648-1654.
14. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J Neurol Neurosurg Psych. 2000;69:217-221.
15. Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psych. 2004;75:1547-1551.
16. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400.
17. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: A practical guide. Clin Rehabil. 2009;23:362-370.
18. Landau WM. Spasticity after stroke: Why bother?. Stroke. 2004;35:1787-1788; author reply 1787-1788.
19. Logan LR. Rehabilitation techniques to maximize spasticity management. Topics Stroke Rehabil 2011;18:203-211.
20. Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: A systematic review. Neurology. 2004;63:1357-1363.
21. Lapeyre E, Kuks JB, Meijler WJ. Spasticity: Revisiting the role and the individual value of several pharmacological treatments. Neuro Rehabil. 2010;27:193-200.
22. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med. 2010;46:401-410.
23. Chua KS, Kong KH. Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: Clinical outcomes. Arch Phys Med Rehabil. 2000;81:1432-1435.
24. Petrillo CR, Knoploch S. Phenol block of the tibial nerve for spasticity: A long-term follow-up study. Int Disabil Studies. 1988;10:97-100.
25. Bodine-Fowler SC, Allsing S, Botte MJ. Time course of muscle atrophy and recovery following a phenol-induced nerve block. Muscle Nerve. 1996;19:497-504.
26. Zafonte RD, Munin MC. Phenol and alcohol blocks for the treatment of spasticity. Phys Med Rehabil Clin North Am. 2001;12:817-832, vii.
27. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-Introduction. Eur J Neurol. 2010;17:1-8.
28. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB, Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: International consensus statement. Eur J Neurol. 2010;17:57-73.
29. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ, Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: International consensus statement. Eur J Neurol. 2010;17:74-93.
30. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691-1698.
31. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41:13-25.
32. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402-2406.
33. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003;84:103-107.
34. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin. 2010;26:1983-1992.
35. KaÎnovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32:259-265.
36. McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, et al. Botulinum toxin a for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009;41:536-544.
37. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, BoNT/TZD Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80:380-385.
38. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996;61:265-269.
39. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, et al. Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257:1330-1337.
40. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26-31.
41. Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovas Dis. 2003;15:289-300.
42. Cardoso E, Pedreira G, Prazeres A, Ribeiro N, Melo A. Does botulinum toxin improve the function of the patient with spasticity after stroke? Arq Neuropsiquiatr. 2007;65:592-595.
43. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Movement Dis. 1994;9:213-217.
44. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29:683-690.
45. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry. 2004;75:1558-1561.
46. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13:35-40.
47. Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil. 2003;84:1194-1199.
48. Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006;87:1509-1515.
49. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099-2109.
50. Schiess MC, Oh IJ, Stimming EF, Lucke J, Acosta F, Fisher S, et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation. 2011;14:38-45.
51. Francisco GE, Yablon SA, Schiess MC, Wiggs L, Cavalier S, Grissom S. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Topics Stroke Rehabil. 2006;13:74-85.
52. Dvorak EM, Ketchum NC, McGuire JR. The underutilization of intrathecal baclofen in poststroke spasticity. Topics Stroke Rehabil. 2011;18:195-202.
53. Pinzur MS, Wehner J, Kett N, Trilla M. Brachioradialis to finger extensor tendon transfer to achieve hand opening in acquired spasticity. J Hand Surg. 1988;13:549-552.
54. Rousseaux M, Buisset N, Daveluy W, Kozlowski O, Blond S. Comparison of botulinum toxin injection and neurotomy in patients with distal lower limb spasticity. Eur J Neurol. 2008;15:506-511.
55. Smania N, Picelli A, Munari D, Geroin C, Ianes P, Waldner A, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med. 2010;46:423-438.